MDRNA to Present at the 8th Annual BIO Investor Forum

BOTHELL, WA--(Marketwire - 10/22/09) - MDRNA, Inc. (NASDAQ:MRNA - News), a leading RNAi-based drug discovery and development company, today announced that J. Michael French, MDRNA's President and Chief Executive Officer, will deliver a corporate presentation and business update at the 8th Annual BIO Investor Forum. The presentation will take place on Thursday, October 29, 2009 at 9:00am Pacific Time (12:00pm Eastern Time) at the Palace Hotel in San Francisco, California. To access the live audio webcast for this conference, please log on to MDRNA's Web site at www.mdrnainc.com approximately 15 minutes prior to the presentation in order to register and download any necessary software. A replay of the presentation will be available within one hour following the live event.For more information about the 8th Annual BIO Investor Forum, please visit: http://www.investorforum.bio.org/opencms/bif/2009/.About MDRNA, Inc.MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the...
Click here to read the whole Article (external link)

MDRNA to Present Data on Tumor Reduction at Cancer Therapy Conference

BOTHELL, WA--(Marketwire - 10/29/09) - MDRNA, Inc. (NASDAQ:MRNA - News), a leading RNAi-based drug discovery and development company, today announced the presentation of data related to its RNAi oncology programs at the 24th Annual Meeting of the International Society for Biological Therapy of Cancer, taking place October 28-31, 2009 at the Gaylord National Hotel and Convention Center in Washington, D.C. Shaguna Seth, Ph.D., Director of Discovery Research and Pharmaceutical Development, will present data detailing an emerging approach to cancer therapy by harnessing RNA interference to silence aberrant expression of genes linked to cancer. "Development of Novel RNAi-based Therapeutics Targeting Survivin for Treatment of Liver and Bladder Cancer," presented by Dr. Seth, describes anti-tumor activity of a proprietary siRNA construct, termed UsiRNA, targeting survivin, a key protein in the progression of cancer, in an orthotopic model of liver cancer and an orthotopic model of bladder cancer. The UsiRNA was delivered with the Company's proprietary DiLA2 liposome formulations via systemic (liver cancer) and local (bladder cancer) administration.In liver cancer, treatment with survivin UsiRNA in DiLA2 liposomes resulted in >60% knockdown of survivin mRNA during twice weekly dosing over a three-week period, and knockdown persisted for an additional three weeks after the last dose. High tumor burden in the vehicle and UsiRNA scrambled control groups prompted study termination at seven weeks, at which time there was a 65% decrease in tum...
Click here to read the whole Article (external link)

Q3 2009 MDRNA, Inc. Earnings Release - Time Not Supplied

Earnings Announcements for Thursday, November 12CompanySymbolTimeConferenceCall3i Group plcIII.LBefore Market Open3SBIO INCSSRXAfter Market CloseListenA.D.A.M., Inc.ADAMTime Not SuppliedListenA2A SpAA2A.MITime Not SuppliedAcciona, S.A.ACXIF.PKBefore Market OpenACSM S P AACS.MITime Not SuppliedADDUS HOMECARE CORPADUSBefore Market OpenListenAdvanSource Biomaterials CorporationASBTime Not SuppliedADVANTAGE OIL & GAS LTDAAVAfter Market CloseAECOMACMBefore Market OpenListenAEFFE SPAAEF.MITime Not SuppliedAEGON N.V.AEGOF.PK01:30 am ETAFC Enterprises, Inc.AFCEAfter Market CloseListenAG GROWTH INTL INCAFN.TOBefore Market OpenAir Transport Services Group, Inc.ATSGTime Not SuppliedListenAldila, Inc.ALDAAfter Market CloseALEO SOLAR AG...
Click here to read the whole Article (external link)

MDRNA, Inc. to Hold Third Quarter 2009 Results Conference Call on Thursday, November 12, 2009 at 4:30 pm Eastern Time

BOTHELL, WA--(Marketwire - 11/05/09) - MDRNA, Inc. (NASDAQ:MRNA - News) announced today that it will host a conference call with investors and security analysts on Thursday, November 12, 2009, at 4:30 pm Eastern Time (1:30 pm Pacific Time) to provide a business update and discuss financial results for the 3rd quarter ended September 30, 2009. To participate in the live conference call, U.S. residents should dial 866-543-6405 and international callers should dial 617-213-8897. The participant passcode for the live conference call is 97970805. To access the 24-hour telephone replay, available approximately two hours after the live event, U.S. residents should dial 888-286-8010 and international callers should dial 617-801-6888. The participant passcode for the replay is 36119088. Alternatively, to access the live audio webcast for this conference call via the Internet, please go to MDRNA's website at http://www.mdrnainc.com under Investors Event calendar or click on the following link: http://phx.corporate-ir.net/phoenix.zhtml?c=83674&p=irol-calendar approximately 15 minutes prior to the conference c...
Click here to read the whole Article (external link)

MDRNA, Inc. Receives NASDAQ Notification

BOTHELL, WA--(Marketwire - 11/12/09) - MDRNA, Inc. (NASDAQ:MRNA - News) announced today that on November 6, 2009 it received a letter from The NASDAQ Stock Market, Inc. notifying the Company that, for ten consecutive business days, based on the Company's Market Value of Listed Securities (MVLS), it did not comply with the $50 million minimum MVLS for continued listing on The NASDAQ Global Market set forth in NASDAQ Marketplace Rule 5450(b)(3)(A). The Company has a grace period of 90 calendar days (until February 4, 2010) in order to regain compliance, which can be achieved if the Company's MVLS closes at $50 million or more for a minimum of ten consecutive business days during this time. MDRNA will continue to be listed on the NASDAQ Global Market during this period. "We believe we are taking all necessary steps to enhance shareholder value and regain compliance with NASDAQ's listing requirements," stated J. Michael French, President and Chief Executive Officer of MDRNA. "Based upon the continued advancement of both our science and oncology programs and our on-going business development efforts, we are confident that we will be able to meet the Nasdaq Global Markets listing requirements within the 90 day grace period."About MDRNA, Inc.MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therap...
Click here to read the whole Article (external link)

MDRNA, Inc. Announces Third Quarter 2009 Financial Results

BOTHELL, WA--(Marketwire - 11/12/09) - MDRNA, Inc. (NASDAQ:MRNA - News) today reported financial results for the three- and nine-month periods ended September 30, 2009. Net loss for the third quarter of 2009 was approximately $7.0 million or $0.17 per share, compared to a net loss of approximately $16.1 million or $0.52 per share for the same period of 2008. The net loss for the nine months ended September 30, 2009 was approximately $7.3 million or $0.20 per share, compared to approximately $46.9 million or $1.62 per share for the prior year same nine-month period. "During the third quarter, we made significant progress in our research and pre-clinical efforts as we continued to advance our oncology programs," said J. Michael French, President and Chief Executive Officer of MDRNA. "In particular, we are encouraged by the recently reported in vivo data on our proprietary compound MRNA-046 which demonstrated sustained reduction in survivin mRNA and inhibition of tumor growth in rodent models of both liver and bladder cancer. In addition, we are reporting, here and on our conference call, that we have observed significant knockdown of a primate liver gene following a single systemic dose of 0.3 mg/kg. We look forward to continuing our rapid progress in both the oncology and non-human primate programs and leveraging our proprietary RNAi discovery engine to create value through both new and expanded research collaborations."FINANCIAL RESULTSRevenueRevenue for the three months ended September 30, 2009 was $0.1 million, ...
Click here to read the whole Article (external link)

MDRNA cuts Q3 loss; gets NASDAQ warning

.contextualWrap{ margin-top:10px;border: 1px solid #528143;background: #7cb45b url(images/contextualAd_backGrad.png) repeat-x bottom;font-family: Arial, Helvetica, sans-serif; } .contextualGradWrap{ background: url(http://images.bizjournals.com/b2/contextualAd_backGrad2.png) repeat-x top;margin: 0px;padding-top: 1px;padding-right: 1px;padding-left: 1px; } .contextualTitle{ background: #72ac54 url(http://images.bizjournals.com/b2/contextualAd_backTitle.png) repeat-x top;padding: 4px 14px; } .contextualMarket{ font-size: 14px;font-weight: bold;color: #0d3500; margin: 0px; padding: 0px; } .contextualContentWrap{ padding-right: 2px;padding-left: 2px; } .contextualContentGradWrap{ background: #FFFFFF url(http://images.bizjournals.com/b2/contextualAd_backGradcontent.png) repeat-x top;margin: 0px;padding-top: 1px;padding-right: 1px;padding-left: 1px;border-top: 1px solid #a7cb93; } .contextualContent{ background: #FFFFFF;padding: 8px 14px;border-bottom: 1px solid #6a9e57; } .contextualContent p{ font-size: 12px;font-weight: normal;color: #606060;margin: 0px;padding: 0px; } .contextualContent ul{ margin: 0px;padding: 0px 0px 0px 14px;list-style: square;color: #124701; } .contextualContent li{ padding-bottom: 6px; } .contextualContent a:link, .contextualContent a:visited { color: #124701;font-weight: bold;text-decoration: underline;font-size: 12px; } .contextualContent a:hover, .contextualContent a:active { color: #900000;text-decoration: none; } .contextualBottom{ height: 22px;background: #498735 url(http://images.bizjournals.com/b2/contextualAd_bcak_Bottom.png) repeat-x top;border-top: 1px solid #a6c59a;padding-top: 3px;text-align: right; } ...
Click here to read the whole Article (external link)

MDRNA, Inc. Earnings Call scheduled for 4:30 pm ET today

Call DetailsMDRNA, Inc. Earnings Conference Call (Q3 2009)Thu, Nov 12, 2009, 4:30 pm EasternAbout MDRNA, Inc. (NasdaqGM:MRNA)MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The company seeks to improve human health by combining RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide therapeutic options. MDRNA's multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology, and bioinformatics. The company is applying this expertise to a single, integrated drug discovery platform that would be the engine for its clinical pipeline and a versatile platform for establishing therapeutic partnerships. MDRNA is also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that might lead to safer and more effective RNAi-based therapeutics. The company combines expertise in siRNA science with proven delivery platforms and a growing IP portfolio, positioning MDRNA as an RNAi therapeutics company and a value-added collaborator for its research partners. It was formerly known as Nastech Pharmaceutical Company Inc. and changed its name to MDRNA, Inc. The company was founded in 1983 and is headquartered in Bothell, Washington.More Info:Quote |Profile |Reports |Research |Insider |...
Click here to read the whole Article (external link)

MDRNA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Notice of Delisting or Failure to Sati

Show all filings for MDRNA, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for MDRNA, INC. 12-Nov-2009Results of Operations and Financial Condition, Notice of Delisting or Failure to Sati Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as ...
Click here to read the whole Article (external link)

New Star Analyst Rankings for MDRNA, Inc.

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...
Click here to read the whole Article (external link)